| 摘要 |
PURPOSE: To prepare a pharmaceutical composition, comprising an INF-α(α-interferon) hybrid and suitable for treating bladder cancer. CONSTITUTION: This pharmaceutical composition comprises a therapeutically effective amount of an IFN-αBBDD or BBDB hybrid (especially an IFN a B1 B2 D3 D4 or IFNαB1 B2 D3 B4 ) and a pharmaceutically permissible carrier. The composition is preferably directly administered into the bladder with, e.g. a catheter for treating surface bladder cancer or parenterally administered in an intravenous or an intramuscular dosage form for treating invasive or metastatic bladder cancer. When the INF-αhybrid is applied as a liposome formulation comprising phopholipids of formula I [(n) is 1-3; R1 and R2 are each a 10-20C alkyl, alkenyl, or acyl; Y<+> is a cation of a pharmaceutically permissible base] and formula II [(n) is 2-4; R1 and R2 are each defined as above; R3 to R5 are each H or a 1-4C alkyl], the ingredients are enriched in bladder cancer cells and the pharmaceutical composition is especially suitable.
|
